Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 517-518 (mars 2008)
Doi : 10.1016/j.jaad.2007.11.015
Research Letter

Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test

Terrence Hunt, BS , Kenneth Clarke, PhD
Allergan, Inc, Irvine, California 

Correspondence to: Terrence Hunt, BS, Research Investigator, Neurotoxin Research Program Biological Sciences, R&D, Allergan, Inc, 2525 Dupont Dr RD3-3B, Irvine, CA 92612-1599

 Disclosures: This study was supported by Allergan, Inc. The authors are employees of Allergan, Inc, the manufacturer of BOTOX.

  The Federal Food, Drug and Cosmetic Act provides that the interstate shipment of any prescription drug that lacks the required FDA approval is illegal (21 USC 355(a)).

Top of the page

© 2008  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline